Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Product › Details

Nubeqa®

	Next higher product group	darolutamide (ODM-201 / BAY-1841788)
	Status	2019-07-31 registration start
	Organisation	Bayer HealthCare (Group)
	Group	Bayer (Group)
	Organisation 2	Orion Corporation
	Group	Orion Corporation (Group)
	Source	Bayer AG. (7/31/19). "Press Release: U.S. FDA Approves Darolutamide, a New Treatment for Men with Non-metastatic Castration-resistant Prostate Cancer [Not intended for U.S. and UK Media]". Berlin.

Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for cancer drug_o

[1] Hookipa Pharma Inc.. (1/29/24). "Press Release: Hookipa Pharma Provides Update on Business Priorities and Oncology Partnership Programs". New York, NY & Vienna....
[2] ImmunityBio, Inc.. (1/2/24). "Press Release: ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million". Culver City, CA....
[3] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
[4] Nanobiotix S.A.. (7/10/23). "Press Release: Nanobiotix Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3". Paris & Cambridge, MA....
[5] Bicycle Therapeutics plc. (6/23/23). "Press Release: Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer". Cambridge & Boston, MA....
[6] Boundless Bio, Inc.. (5/16/23). "Press Release: Boundless Bio Announces $100 Million Oversubscribed Series C Financing Co-led by Leaps by Bayer and RA Capital Management". San Diego, CA....
[7] Pieris Pharmaceuticals, Inc.. (4/17/23). "Press Release: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting". Boston, MA....
[8] Leap Therapeutics, Inc.. (1/17/23). "Press Release: Leap Therapeutics Acquires Flame Biosciences". Cambridge, MA....
[9] Bicycle Therapeutics plc. (1/4/23). "Press Release: Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer". Cambridge & Bos...
[10] Merck & Co., Inc.. (12/21/22). "Press Release: Lynparza (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer". Rahway, NJ....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]